Table S4. Patient AML clinical data

I.D.	Gender	Age (years)	De novo vs. Secondary	Type of Sample	FAB Subtype	Karyotype	Additional Molecular Markers
AML-1	M	56	De novo	Diagnosis	M4	46, XY[20]	NPM1, FLT3-ITD
AML-2	M	43	Secondary	Diagnosis	Unclassified	46, XX[20]	NPM1
AML-3	F	66	Secondary	Diagnosis	nd	46, XX[17]	nd
AML-4	M	32.7	De novo	Diagnosis	M1	46,XY,ider(7)(q10)del(7)(q21)[20]	nd
AML-5	M	62	De novo	Diagnosis	M4	46,XY[20]	na
AML-6	M	78	De novo	Diagnosis	M1	46, XY[20]	na
AML-7	M	64	De novo	Diagnosis	M1	46, XY[21]	FLT3-ITD
AML-8	F	55	Secondary	Diagnosis	Unclassified	46,XX,t(9;11)(p22;q23)[10]	nd
AML-9	F	59.3	De novo	Diagnosis	M4Eo	46,XX,inv(16)(p13.1q22)[9]/46,XX[4]	nd
AML-10	M	27	De novo	Diagnosis	M0	47,XY,+4[20]	nd
AML-11	M	74	MLL	Diagnosis	MLL	X,-Y,der(5)t(1;5)(q25;q13),del(8)(p23),add(9)(p22)[20]	nd
AML-12	M	72	Secondary	Diagnosis	nd	45, X-Y[20]	nd
AML-13	M	72.5	Secondary (radiation for prostate cancer)	Diagnosis	M5a	46,XY[20]	na
AML-14	M	43	De novo	Relapse	M4	46, XY[21]	NPM1, FLT3-TKD
AML-15	F	55	De novo	Relapse	M4	Abnormal 5 AND 43~47,XX,-2,-3,add(3)(p11),-4,del(4)(q21),+del(4)(q21),del(5)(q13),del(7)(q22q34),+8,-10,add(10)(p13),-12,del(14)(q24q32),-17,-20,+mar1,+mar2,+mar3[cp10] AND Abnormal 7	nd
AML-16	M	33.6	De novo	Diagnosis	M2	46,XY,inv(3)(q21q26.2),t(9;22)(q34;q11.2)[9]/46,XY[1]	BCR-ABL p210 positive
AML-17	M	80.3	De novo	Diagnosis	M0	45,X,-Y[13]/46,XY[7]	nd
AML-18	F	94.7	De novo	Diagnosis	M2	46,XX,t(8;21)(q22;q22)[8]	AML-ETO+; KIT+
AML-19	F	61.9	De novo	Diagnosis	M5a	46,XX[20]	NPM1, FLT3-ITD
AML-20	F	78.8	De novo	Diagnosis	Unclassified	nd	nd
AML-21	M	63.7	De novo	Diagnosis	Unclassified	46,XY[20]	NPM1, FLT3-ITD low
AML-22	M	73.2	Secondary (prostate, colon,MDS)	Diagnosis	M2	46,XY,+8[9]	nd
AML-23	M	65.3	De novo	Diagnosis	M4Eo	46,XY,inv(16)(p13.1q22)[10]/46,XY[6]	CBFB-MYH11 positive; no KIT mutn (exon 8/17)
AML-24	M	81.5	De novo	Diagnosis	M1	46,XY[20]	na
AML-25	F	68	Secondary (MDS)	Diagnosis	M0	normal	nd
AML-26	M	64	De novo	Diagnosis	MDS	47,XY,+8[2]/46,XY[20]	nd
AML-27	F	74.8	De novo	Diagnosis	Unclassified	46,XX[20]	NPM1
AML-28	M	65	De novo	Diagnosis	Unclassified	Abnormal 5 AND Abnormal 7 AND 43~45,X,-Y,t(1;5)(q21;p13),t(1;6)(q21;p25),-2,add(2)(p21),add(3)(q27),del(3)(q27),add(4)(p16),del(4)(q33),del(5)(q31),add(6)(p25),del(6)(q21),-7,add(7)(q36),del(7)(q22),-8,add(8)(q24.3),del(8)(?q23),+del(8)(q22),add(9)(p22),add(9)(q34),add(11)(p15),add(12)(p13),-16,add(16)(p13.3),-17,der(17)t(11;17)(q13;p13),add(18)(q23),der(19)t(11;19)(q13;q13.3),-21,add(22)(p11.2),+4mar[cp20]	nd
AML-29	F	51	De novo	Diagnosis	Unclassified	47,XX,+8[14]	NPM1 neg, FLT3-TKD neg, FLT3-ITD pos